Why the study?
Does cytomegalovirus (CMV) infection increase the risk of graft atherosclerosis and mortality in cardiac allograft recipients?
Does cytomegalovirus (CMV) infection increase the risk of graft atherosclerosis and mortality in cardiac allograft recipients?
Cytomegalovirus infection is highlighted as a significant risk factor for the development of accelerated graft atherosclerosis and subsequent mortality in cardiac transplant recipients.
No takes yet. Share an insight, caveat, or question.
May prompt closer posttransplant CMV monitoring; leaves open whether prophylaxis reduces graft atherosclerosis or mortality.
Mark T. Grattan (1991) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: